Arcus Biosciences stock holds steady as new ARC-20 kidney cancer data

Arcus Biosciences stock holds steady as new ARC-20 kidney cancer data
Arcus Biosciences stock holds steady today

Arcus Biosciences announced on September 23, 2026, new data from its ARC-20 platform study demonstrating promising results for its kidney cancer therapy. Separately, the stock is little changed on the day, trading near $22.14.

Highlights

  • Arcus Biosciences reported new ARC-20 study data showing investigational therapy casdatifan outperformed existing kidney cancer treatments in all studied lines.
  • 44 of 54 analysts rate Arcus Biosciences stock a buy, with a median price target of $43 and none at sell.
  • Arcus Biosciences stock is little changed on the day, trading near $22.14.

Arcus Biosciences announced new data from its ARC-20 platform study on September 23, 2026. The data, shared by the company, showed that the investigational molecule casdatifan, whether used alone or in combination, outperformed existing treatments when applied as first-, second- and late-line therapy for kidney cancer. The ARC-20 study is focused on casdatifan as a next-generation HIF-2α inhibitor for clear cell renal cell carcinoma in multiple lines of treatment, according to BioSpace.

Bearish structure holds as price stalls below key averages

Shares of Arcus Biosciences opened with a gap up from $22.13 to $22.51 before giving back part of that move. Price remains below its MA-20, MA-50, and MA-200, which maintains a bearish daily structure. With RSI at 30.6 nearing oversold territory, the recent decline appears to be getting stretched. The nearest support is the weekly low at $21.4.

Downside odds dominate as traders watch the $21.4 support level

To gauge whether the event is being priced in, traders should watch for a close above $24.03 to confirm acceptance or a drop below $21.4 to indicate rejection. In the current session, shares opened at $22.51, up from the previous close of $22.13, but have since pulled back. There was a sharp move higher over the past week without a sustained trend; even so, for the coming trading week, the upside probability is less than 20%, while the downside probability is more than 80%, with an expected range of $20.96 to $23.31. On the weekly chart the longer-term picture stays mixed.

Previously it was reported that Arcus Biosciences maintained a broadly bullish technical structure despite some near-term volatility. The latest data release from the ARC-20 study adds a new dimension, but with price action now below major moving averages and downside probability elevated for the coming week, traders should monitor whether support at $21.4 holds to gauge further risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.